Contents

Blossoms on a Healthy Plant....1

Epidemiology and Biostatistics 1
Association and Causation....2

The Central Core of Epidemiology....3
Scurvy....4
Cholera 5
Causality and Common Sense 6

Biostatisticians and Sampling Error 7

Cooperation Between the Disciplines....7

The Eye of the Beholder....10
Controversy 1: Biased by Nature?....10
The Supremacy of Mathematics? 12

Hammer Blows....13

The Rise and Decline of Significance Testing....14

Advice to the Physician–Scientist....17

References 18

Chapter 1. Fundamentals of Clinical Trial Design 21

1.1 The Definition of a Clinical Trial 21

1.2 Principles of Randomization....22
1.2.1 Random Selection of Subjects from the Population 22
1.2.2 Random Allocation of Therapy 23
1.2.3 Stratified Randomization 25

1.3 The Use of Blinding....25
1.3.1 Single-Blinded Trials....26
1.3.2 Double-Blind Studies....27
1.3.3 Arthroscopy and the Art of the Double-Blind 28

1.4 Interim Monitoring of Clinical Trials 30

1.4.1 The Need for Trial Monitoring 30
1.4.2 Test Statistic Trajectories....31
1.4.3 Group Sequential Procedures....37
1.4.4 Stochastic Curtailment....39
1.5 Intention to Treat Analyses....39
1.6 Measures of Effect....40
1.7 The Goal of Statistical Hypothesis Testing 41
1.8 Sampling Error and Significance Testing....42
1.9 Statistical Power 43
1.10 Sample Size Computations....44
1.11 Analysis 44
References 45

Chapter 2. Multiple Analyses and the Random Experiment 47

2.1 Introduction 49
2.1.1 Advisory Committee Discussions....50
2.2 Prevalent Perceptions....50
2.3 Calling Your Shot....51
2.3.1 Vesnarinone 52
2.3.2 Losartan 54
2.3.3 Amlodipine 55
2.3.4 Carvedilol 56
2.3.5 Experimental Inconsistencies 58
2.4 Samples as Reflections 59
2.5 Representative Samples That Mislead? 60
2.6 Estimators....63
2.7 Random Experiments....64
2.7.1 What Is a Random Protocol? 64
2.7.2 Crippled Estimators in Random Experiments....65
2.7.3 Untrustworthy....65
2.8 Collecting the Entire Population....66
2.9 Regulatory Example 67
2.10 Additional Comments....68
2.10.1 Don't Rush to Judgment 68
2.10.2 Random Research in Extremis....69
2.10.3 Requirements of Investigators and Readers....69
2.11 Conclusions 70

Problems 70

References 71

Chapter 3. The Lure and Complexity of Multiple Analyses 75

3.1 Definition of Multiple Analyses 75

3.2 Why Do Multiple Analyses? 76
3.2.1 Logistical Efficiency 77
3.2.2 Epidemiologic Strength 77
3.2.3 The Need to Explore 79

3.3 Hypothesis Testing in Multiple Analyses 80
3.3.1 Nominal P-Values 80
3.3.2 The Error of Interest: Familywise Error 81
3.3.3 Initial Computations for ξ 82
3.3.4 FDA and Strength of Evidence 84

3.4 Is Tight Control of the FWER Necessary? 85

3.5 Community Protection 86

3.6 Efficacy and Drug Labels 89

3.7 The Bonferroni Inequality 90

3.8 Who Was Bonferroni? 93

3.9 Alternative Approaches 94
3.9.1 Sequentially Rejective Procedures 94
3.9.2 Who Chooses the α Level Threshold? 95
3.9.3 Resampling P-Values 98

3.10 Conclusions 99

Problems 100

References 101

Chapter 4. Multiple Analyses and Multiple Endpoints 105

4.1 Introduction 105

4.2 Important Assumptions 106

4.3 Clinical Trial Result Descriptors 106
4.3.1 Positive and Negative Trials 106
4.3.2 Null Results Versus Uninformative Results 107

4.4 The Strategy for Multiple Endpoint Analysis 108

4.5 Tactic 1: Triage the Endpoints 110
4.5.1 The Process of Endpoint Triage 111
4.5.2 An Example of the Endpoint Triage Process 111

4.5.3 Other Motivations for Triaging Endpoints....112
4.5.4 Endpoint Triaging and Labeling Indications....113

4.6 Endpoint Descriptors....113
4.6.1 Primary Endpoints....114
4.6.2 Secondary Endpoints....115
4.6.3 Exploratory Endpoints....116
4.6.4 Choose Wisely....119
4.6.5 Planning Well to Learn Well....119

4.7 Mapping Out the Manuscript....121
4.7.1 The Design Manuscript....121
4.7.2 Laying Out the Manuscripts....122

4.8 Multiple Primary Endpoint Interpretations....124

4.9 Tactic 2: Differential α Allocation....126
4.9.1 Differential α Rate Allocation....127
4.9.2 Clinical Decisions in Allocating α....130
4.9.3 Example 1: Different Community Standards....131
4.9.4 Example 2: The Underpowered Environment....135
4.9.5 Example 3: Efficacy Reconsideration....139
4.9.6 Example 4: Multiple Endpoints....143

4.10 Multiple Analyses....145
4.10.1 Example....146

4.11 Theory Versus Reality....148

Problems....152

References....153

Chapter 5. Introduction to Multiple Dependent Analyses I....155

5.1 Rationale for Dependent Testing....155
5.1.1 Review....155

5.2 The Notion of Dependent Analyses....156
5.2.1 The Nature of Relationships....156
5.2.2 Endpoint Coincidence and Correlation....158
5.2.3 Surrogate Endpoint Definition....162

5.3 Literature Review....163
5.3.1 Tukey's Procedure and Related Ad Hoc Computations....163

5.4 Hypothesis Test Dependency: Notation....166

5.5 The Independence Scenario....167

5.6 Demonstration of Perfect Dependence....169

5.7 Scenario Contrasts....171

5.8 Creation of the Dependency Parameter 172
5.9 Solving for α_2 as a Function of D 176
5.10 Example 1: Implantable Cardiac Devices....177
5.11 Example 2: The CURE Trial 181
5.12 Example 3: Paroxysmal Atrial Fibrillation....183
5.13 Choosing the Dependency Parameter....187
5.13.1 Overestimation of Dependency Parameter 187
5.13.2 Guides to Choosing the Dependency Parameter....188
5.14 Hyperdependent Analyses 191
5.14.1 Hyperdependence as a Disadvantage....191
5.14.2 Hyperdependence as an Advantage 193
Problems....195
References 196

Chapter 6. Multiple Dependent Analyses II 199

6.1 Three Multidependent Analyses..... .199
6.1.1 Example of Dependency Among Three Endpoints....202
6.2 The Solution for Four Dependent Analyses....205
6.3 K Multidependent Analyses 206
6.4 Conservative Dependence 207
6.5 Generalization of the Bonferroni Inequality 209
6.6 Subclass Dependence....210
6.6.1 Solutions for Two Subclasses 210
6.6.2 Therapy for CHF....212
6.7 Conclusions 216
Problems....217
References 218

Chapter 7. Introduction to Composite Endpoints 219

7.1 Introduction 219
7.2 Definitions and Motivations 220
7.3 Notation....220
7.4 Motivations for Combined Endpoints....220
7.4.1 Epidemiologic Considerations....221
7.4.2 Sample Size Concerns 221
7.4.3 Improved Resolving Power 223

7.5 Properties of Combined Endpoints 225
7.6 Component Endpoint Coherence 225
7.7 Coincidence 225
7.8 Mutual Exclusivity and Disparate Events 227
7.9 The Problem with Mutual Exclusivity 228
7.10 Balancing the Separation 229
7.11 Component Endpoint Equivalence 230
7.12 Therapy Homogeneity 232
7.13 Composite Endpoint Measurement Rules 234
7.14 Prospective Identification 234
7.15 Combined Endpoint Ascertainment 235
7.16 Conclusions 236
Problems 237
References 237

Chapter 8. Multiple Analyses and Composite Endpoints 239

8.1 Examples of Composite Endpoint Use 239
8.2 Lipid Research Clinics 240
8.3 UKPDS 241
8.4 HOPE 245
8.5 Principles of Combined Endpoint Use 247
8.6 α Allocation and Combined Endpoints 249
8.6.1 Familywise Error Control Procedures 249
8.6.2 Multiple Analyses and Composite Endpoint Distress 249
8.7 Example 1: Design for a Heart Failure Trial 251
8.8 Composite Endpoints: Diabetes Mellitus 256
8.9 "Soft" Components 261
8.10 Conclusions 263
Problems 264
References 264

Chapter 9. Introduction to Subgroup Analyses 267

9.1 Introduction 267

9.2 Definitions and Basic Concepts....268
9.2.1 Subgroups Versus Subgroup Strata....268
9.3 Interpretation Difficulties....269
9.4 Random Subgroups....269
9.5 Stratified Randomization....271
9.6 Proper Versus Improper Subgroups....274
9.7 "Intention-to-Treat" Versus "As Treated"....278
9.8 Example 1: Diabetes Mellitus in SAVE....279
9.9 Subgroup Result Depiction....281
Problems....283
References....284

Chapter 10. Subgroups II: Effect Domination and Controversy....287

10.1 Effect Domination Principle....287
10.2 Assessment of Subgroup Effects....288
10.2.1 Effect Modification and Interaction Analyses....288
10.2.2 Within-Stratum Effects....290
10.3 Problematic Subgroup Analyses....291
10.4 The MERIT Trial....292
10.5 Ethnicity and ACE-i therapy....295
10.6 The NETT Study....298
10.7 The Difficulties Continue....300
Problems....301
References....301

Chapter 11. Subgroups III: Confirmatory Analyses....303

11.1 Introduction....303
11.2 Focus on Stratum-Specific Effects....304
11.3 Confirmatory Analyses Requisites....305
11.4 Incorporating Subgroup Dependency....305
11.4.1 Therapy Homogeneity in Subgroup Evaluations....307
11.5 Subgroup Stratum-Specific Endpoints....310
11.5.1 Choosing the Subcohort Endpoints....311
11.5.2 Example....311

11.5.3 Dependency Parameter's Minimal Impact....316
11.6 Differential Event Rate....316
11.6.1 Event Rate Differences....318
11.7 Differential Efficacy....322
11.7.1 The Relationship Between Efficacy and Sample Size....322
11.7.2 Choosing an Efficacy Level....324
11.7.3 Matching Clinical and Statistical Significance....327
11.7.4 Example....328
11.8 The Differential Use of Event Precision....332
11.8.1 Sample Sizes for Continuous Endpoints....332
11.8.2 Cohort-Dependent Precision....333
11.9 Conclusions....335
Problems....337
Note....337
References....339
Chapter 12. Multiple Analyses and Multiple Treatment Arms....341
12.1 Introduction and Assumptions....341
12.2 Literature Review....342
12.3 Treatment Versus Treatment....343
12.4 Dose–Response Effects....350
12.5 Conclusions....356
References....357
Chapter 13. Combining Multiple Analyses....359
13.1 Introduction....359
13.2 Creating a Multiple Analysis Environment....360
13.3 Composite Endpoints Within Subgroups....363
13.4 Majority Subgroups in Clinical Trials....366
13.5 Atherosclerotic Disease Trial Designs....370
13.6 Multiple Treatment Groups Revisited....375
References....378
Chapter 14. Conclusions: The Two-Front War....379
14.1 Compromise and Sampling Error....379

14.2 The Handcuffs 381
References 384

Appendix A. Case Reports and Causality 385
A.1 Causality Tenets....387
A.2 Do Case Reports Prove Causality? 390
References 392

Appendix B. Estimation in Random Research....393
B.1 Introduction....393
B.2 Dichotomous Clinical Events....394
B.2.1 Event Rate for the Fixed Research Paradigm....394
B.2.2 Event Rates in Random Research 397
B.3 Hypothesis Testing....401

Appendix C. Relevant Code of Federal Regulations 403
C.1 Indications for Prescritpion Drugs 403
C.2 Adequate and Well-Controlled Trials 404

Appendix D. Sample Size Primer 409
D.1 General Discussion of Sample Size 409
D.2 Derivation of Sample Size 412
D.3 Example 414
References 415

Appendix E. Additional Dependent Hypothesis Testing Results....417
E.1 Derivation of Dependence for $K = 4$ 417
E.2 Induction Arguments....419
E.3 Additional Recursive Relationships 423
References 429

Index....431